Bax inhibitor peptide V5
Cat. No. 1785
Biological ActivityCell-permeable synthetic peptide inhibitor of Bax conformational change and mitochondrial translocation. Designed based on the Bax-binding domain of human Ku70. Inhibits Bax-mediated apoptosis in vitro. Shown to inhibit anti-cancer drug-induced apoptosis in vitro. Negative control (Cat. No. 1787) available.
Licensing InformationSold under license
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Sawatzky et al (2006) The involvement of the apoptosis-modulating proteins ERK 1/2, Bcl-xL and Bax in the resolution of acute inflammation in vivo. Am.J.Pathol. 168 33. PMID: 16400007.
Yoshida et al (2004) Bax-inhibiting peptide derived from mouse and rat Ku70. Biochem.Biophys.Res.Commun. 321 961. PMID: 15358121.
If you know of a relevant reference for Bax inhibitor peptide V5 please let us know.
Citations are publications that use Tocris products. Selected citations for Bax inhibitor peptide V5 include:
Lee et al (2010) Angiotensin-II-induced apoptosis requires regulation of nucleolin and Bcl-xL by SHP-2 in primary lung endothelial cells. J Cell Sci 123 1634. PMID: 20406888.
Do you know of a great paper that uses Bax inhibitor peptide V5 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Bax inhibitor peptide V5, supplier, inhibitors, inhibits, Bax-mediated, apoptosis, Bcl-XL, Mcl-1, Bcl-2, Family, Bax, inhibitor, peptideV5, Tocris Bioscience, Bcl-2 Family Inhibitor products
Find multiple products by catalog number
June 14 - 17, 2017
Boston, MA, USA